Lisata Therapeutics, Inc. (LSTA) Balance Sheet

NASDAQ: LSTAAssets, liabilities, debt and equity over 10 years.

LSTA balance sheet, 2025

December 31, 2025 · U.S. dollars

$17.7M assets = $3.1M liabilities + $14.6M equity

What it owns$17.7MCash & ST investments: $16.0M (89.9%)Cash & ST investments$16.0M · 90%Receivables: $700,000 (3.9%)Other current: $1.0M (5.9%)Other current $1.0MPP&E: $18,000 (0.1%)Other non-current: $23,000 (0.1%)=How it is financed$17.7MCurrent liabilities: $3.1M (17.3%)Current liabilities$3.1M · 17%Other LT liabilities: $72,000 (0.4%)Shareholders’ equity: $14.6M (82.3%)Shareholders’ equity$14.6M · 82%

Both columns are drawn to the same scale: what LSTA owns equals what it owes plus shareholders’ equity. Hover a block for its value.

LSTA financial health

Current ratio5.76
Comfortable · current assets cover current liabilities 5.76×
Equity / assets83.7%
Equity-funded · of assets funded by shareholders
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

LSTA balance sheet trends, 2016–2025

Lisata Therapeutics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$51.8M2016$17.7M2025−11.2%/yr
Total liabilities$47.8M2016$3.1M2025−26.1%/yr
Shareholders’ equity$4.9M2016$14.9M2025+13.2%/yr
Cash & short-term investments$14.7M2016$16.0M2025+0.9%/yr
Total debt$6.8M2016$137,0002024−38.6%/yr
Net cash (debt)$7.9M2016$31.1M2024+$23.2M
Working capital$5.1M2016$14.6M2025+$9.5M
Book value per share$25.012021$1.712025−48.9%/yr
Current ratio1.2620165.762025+4.50
Debt / equity1.3920160.002024−1.39
Shares outstanding3.7M20218.7M2025+23.9%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

LSTA assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

LSTA liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

LSTA debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

LSTA balance sheet

Lisata Therapeutics, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$16.0M$31.2M$50.5M$69.2M$95.0M$34.6M$25.2M$43.1M$55.1M$14.7M
Cash & equivalents$16.0M$16.2M$22.6M$32.2M$24.6M$16.5M$14.0M$10.3M$29.2M$14.7M
Short-term investments$0$15.0M$27.9M$37.1M$70.3M$18.1M$11.1M$32.8M$25.9M—
Receivables$700,000$900,000$1.0M$0$0$0$0$0$234,461$138,774
Inventory$0$0$0$0$0$0$0$0$5.0M$3.6M
Other current assets$1.0M$2.4M$2.4M$2.6M$1.2M$758,000$815,000$1.1M$790,514$6.2M
Total current assets$17.7M$34.6M$53.9M$71.9M$96.2M$35.3M$26.0M$44.1M$61.1M$24.6M
Property, plant & equipment (net)$18,000$72,000$175,000$296,000$62,000$57,000$100,000$165,000$256,900$17.1M
Goodwill & intangible assets$0$192,000$263,000$334,000$0$0$0$0$0$9.3M
Long-term investments$0$0$0$0$0$0$0$0$0$0
Other non-current assets$23,000$160,000$332,000$528,000$764,000$614,000$1.1M$309,000$2.0M$713,572
Total assets$17.7M$35.0M$54.7M$73.0M$97.0M$36.0M$27.2M$44.6M$63.4M$51.8M
Liabilities
Accounts payable$1.0M$1.3M$2.4M$2.7M$1.9M$1.0M$1.5M$762,000$1.3M$2.2M
Short-term debt—$137,000$168,000$180,000$229,000$370,000$354,000—$159,000$3.7M
Deferred revenue——————$2.5M——$5.1M
Total current liabilities$3.1M$5.6M$6.6M$6.4M$4.5M$3.5M$6.0M$5.6M$9.3M$19.5M
Long-term debt$0$0$0$0$0$0$0$0$0$0
Lease obligations$0$137,000$168,000$485,000$714,000$624,000$354,000———
Other long-term liabilities$72,000$72,000$210,000$327,000$485,000$254,000$624,000$1.5M$3.9M$28.3M
Total liabilities$3.1M$5.7M$6.8M$6.7M$5.0M$3.8M$6.6M$7.1M$13.2M$47.8M
Shareholders' equity
Common stock & paid-in capital$9,000$8,000$8,000$8,000$4,000$19,000$11,000$10,000$9,484$8,206
Retained earnings (deficit)−$564.7M−$548.1M−$528.1M−$507.2M−$453.0M−$425.6M−$417.4M−$398.0M−$381.8M−$404.8M
Accumulated other comprehensive income−$37,000−$81,000−$42,000−$29,000−$70,000−$13,000$2,000−$32,000−$27,978$0
Minority interest−$254,000−$254,000−$254,000−$254,000——————
Total shareholders' equity$14.9M$29.6M$48.1M$66.6M$92.3M$32.5M$20.8M$37.7M$50.5M$4.9M
Key figures
Total debt—$137,000$168,000$485,000$714,000$624,000$978,000—$159,180$6.8M
Net cash (debt)—$31.1M$50.4M$68.7M$94.3M$33.9M$24.2M—$54.9M$7.9M
Working capital$14.6M$29.0M$47.3M$65.5M$91.7M$31.8M$20.0M$38.5M$51.8M$5.1M
Tangible book value$14.9M$29.4M$47.9M$66.2M$92.3M$32.5M$20.8M$37.7M$50.5M−$4.4M
Book value per share$1.71$3.55$5.96$12.85$25.01—————
Shares outstanding8.7M8.3M8.1M5.2M3.7M—————
Current ratio5.766.168.1811.2621.2710.084.357.856.561.26
Quick ratio5.425.737.8210.8521.009.864.217.665.940.76
Debt / equity—0.000.000.010.010.020.05—0.001.39
Equity / assets83.7%84.5%88.0%91.2%95.1%90.3%76.7%84.6%79.7%9.4%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 12, 2026); data from EODHD.

LSTA financial position

At the end of fiscal 2025 (December 31, 2025), Lisata Therapeutics had total assets of $17.7 million (down 49.3% from a year earlier), total liabilities of $3.1 million and shareholders' equity of $14.9 million. Its current ratio was 5.76. In the latest quarter (ended June 30, 2026) total assets were $11.0 million and equity $8.2 million.

Related: LSTA income statement, LSTA cash flow statement, LSTA key metrics. See the LSTA stock overview for the latest quote and news.

LSTA balance sheet FAQ

What are Lisata Therapeutics's total assets?

Lisata Therapeutics reported total assets of $17.7 million at the end of fiscal 2025 (December 31, 2025), compared with $35.0 million a year earlier.

How much cash does Lisata Therapeutics have?

Lisata Therapeutics held $16.0 million in cash and short-term investments at the end of fiscal 2025.

What is Lisata Therapeutics's book value?

Lisata Therapeutics's shareholders' equity (book value) was $14.9 million at the end of fiscal 2025, or $1.71 per share.

What is Lisata Therapeutics's current ratio?

Lisata Therapeutics had current assets of $17.7 million and current liabilities of $3.1 million, a current ratio of 5.76 (it can cover its short-term obligations).

Biotechnology: balance sheet